Shannon Youngblood

SNMMI-TS Awards Ceremony and Business Meeting

Abstract placeholder. Drop in the official SNMMI session abstract once published.

Day and time to be confirmed against the SNMMI program.

1. Which trial readout in 2026 will most reshape the field?
2. What's the most overlooked piece of infrastructure in this ecosystem?
3. Where do you see PSMA-targeted therapy hitting its real ceiling, clinical or operational?

Generated by a mock model. Wired to Anthropic when the API key is in place.

What we're seeing

• Endpoints News · 2026-08-01
  Shannon Youngblood joins editorial board of European Journal of Nuclear Medicine
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• Reuters Health · 2026-11-22
  Shannon Youngblood cited in NEJM perspective on theranostic standardization
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• BioPharma Reporter · 2026-02-11
  Shannon Youngblood co-authors review on PSMA in Journal of Nuclear Medicine
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• FierceBiotech · 2026-01-20
  Shannon Youngblood presents updated trial data at ASCO Annual Meeting
  Coverage notes the company's growing footprint in the radioligand therapy space.
• STAT News · 2026-04-01
  Shannon Youngblood delivers keynote at International Theranostics Congress
  Coverage notes the company's growing footprint in the radioligand therapy space.

Mocked while we wire the Exa integration. Headlines are illustrative.